Skip to main content
. 2020 Mar 31;109(9):1079–1098. doi: 10.1007/s00392-020-01633-w

Fig. 1.

Fig. 1

Current model on pathophysiology and management of comorbidities and risk factors in HFpEF. Cumulative expression of the shown comorbidities and risk factors can cause systemic inflammation which can then lead to development of HFpEF [2]. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, MRA mineralocorticoid receptor antagonist, PDE5 hosphodiesterase-5, sCG soluble guanylate cyclase, SGLT2 sodium-glucose cotransporter-2.

Figure modified according to Tschöpe et al. [4] and Lam et al. [9]